ARS Pharmaceuticals Inc SPRY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPRY is a good fit for your portfolio.
News
-
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy
-
ARS Pharmaceuticals to Meet With FDA on Neffy Rejection
-
ARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback
-
ARS Pharmaceuticals stock falls toward record selloff after FDA issues surprise CRL, requesting additional studies
-
ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray
-
ARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy
-
ARS Pharmaceuticals Gets FDA Committee Meeting for Neffy
Trading Information
- Previous Close Price
- $8.09
- Day Range
- $8.10–8.66
- 52-Week Range
- $2.55–11.27
- Bid/Ask
- $8.35 / $9.00
- Market Cap
- $805.79 Mil
- Volume/Avg
- 520,298 / 726,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.ars-pharma.com
Comparables
Valuation
|
Metric
|
SPRY
|
ICVX
|
INVA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.30 |
Price/Book Value | 3.49 | 3.30 | 1.43 |
Price/Sales | — | — | 4.27 |
Price/Cash Flow | — | — | 7.99 |
Price/Earnings
SPRY
ICVX
INVA
Financial Strength
|
Metric
|
SPRY
|
ICVX
|
INVA
|
|---|---|---|---|
Quick Ratio | 95.84 | 17.59 | 7.28 |
Current Ratio | 96.92 | 18.06 | 9.03 |
Interest Coverage | — | — | 10.31 |
Quick Ratio
SPRY
ICVX
INVA
Profitability
|
Metric
|
SPRY
|
ICVX
|
INVA
|
|---|---|---|---|
Return on Assets (Normalized) | −17.45% | −29.30% | 14.79% |
Return on Equity (Normalized) | −18.04% | −31.87% | 29.29% |
Return on Invested Capital (Normalized) | −18.02% | −34.69% | 16.71% |
Return on Assets
SPRY
ICVX
INVA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfrpgxdgj | Wbbr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wsfmldt | Nwfpx | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlmpkhrl | Drfthk | $97.8 Bil | |
MRNA
| Moderna Inc | Dcxxhhbd | Sfrzq | $41.3 Bil | |
ARGX
| argenx SE ADR | Lltxdqvb | Brl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gpzbwkd | Zddvx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hrhmmzv | Mjvrpl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hvsxkbhh | Yqxxxy | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jpfsvcysbp | Dtgnx | $12.5 Bil | |
INCY
| Incyte Corp | Wmynvcpp | Gjbwgmv | $11.6 Bil |